Additionally, compounds such as PL 1-3 (Li et al., 2023) and Empagliflozin (Long et al., 2024) have garnered attention for their ability to upregulate SIRT1, enhance mitochondrial function, and reduce oxidative stress and senescence markers, thereby mitigating the progression of liver diseases such as MASLD. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.